Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Administration (NMPA) ...

13, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) (“Akeso” or the “Company”) is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical ...

model of osteogenic differentiation was used in combination with recombinant IL-17 cytokines, T-cell supernatants or serum from patients with AS. IL-17A, IL-17F and bimekizumab monoclonal antibodies ...

2009), and several biologics targeting the IL-17/IL-23 axis were approved for the treatment of psoriatic diseases (Bai et al., 2019). AK111 is a humanized IgG1 monoclonal antibody (mAb) that ...

HONG KONG, Feb. 14, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National ...

The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...

Two of Bambusa’s bispecific antibody candidates for immunological and inflammatory disorders are set to enter the clinic in ...

Antibodies that interfere with IL-6 function Tocilizumab is a monoclonal antibody directed against the IL-6 receptor that has established benefit in RA both with regards to clinical efficacy and ...

4 strains, but the serological basis for GII.17 antigenic diversity has not been studied in children. Utilizing samples from a birth cohort, we investigated antibody and B-cell responses to GII.17 ...

Among the cytokines produced by T cells, interleukin (IL)-17A (previously known as IL-17) and IL-17F constitute the signature cytokines of the newly described Th17 T helper cell subset. While the ...

Compugen's innovative approach targets under-explored immune pathways like PVRIG and IL-18 binding protein. Read why I'm ...